Kestra Advisory Services’s Pacific Biosciences PACB Stock Holding History

Kestra Advisory Services’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.3K	Buy	35,298 +500	+1%	+$727	﹤0.01%	3207
2026 Q1	$45.9K	Sell	34,798 -60	-0.2%	-$107	﹤0.01%	3060
2025 Q4	$65.2K	Buy	34,858 +652	+2%	+$1.25K	﹤0.01%	3769
2025 Q3	$43.8K	Buy	+34,206	New	+$46.3K	﹤0.01%	2865

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kestra Advisory Services's PACB Position: Q2 2026 in Review

Kestra Advisory Services increased its Pacific Biosciences (PACB) stake by 1.4% in Q2 2026, buying an estimated $727 and bringing the position to 35,298 shares worth $59.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3207.

Kestra Advisory Services first reported a position in PACB in Q3 2025 and has held it in 4 quarters since. The position peaked at $65.2K in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Kestra Advisory Services held 35,298 shares of Pacific Biosciences worth $59.3K as of Q2 2026.
Kestra Advisory Services bought 500 Pacific Biosciences shares in Q2 2026, an estimated $727.
Pacific Biosciences made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #3207 holding.
Kestra Advisory Services first reported a position in Pacific Biosciences in Q3 2025 and has held it in 4 quarters since.
Kestra Advisory Services's Pacific Biosciences position peaked at $65.2K in Q4 2025.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.